CTOs on the Move

Ariana Pharma

www.arianapharma.com

 
Ariana is a spin-off of the prestigious Pasteur Institute offering a unique and powerful association rules-based analytical approach to clinical datasets and biomarker discovery that is complementary to statistical analysis.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Mirna Therapeutics

Mirna Therapeutics, Inc. (Mirna) is a biotechnology research and development company focused on miRNA-directed oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and a broad IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.

Cerber-Net

Cerber-Net is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VinCro Clinical Management Services

VinCro Clinical Management Services is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Revvity

At Revvity, “impossible” is inspiration, and ""can`t be done"" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what`s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With more than $3 billion in revenue and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Kronos Bio

Kronos Bio is clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity.